Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?

Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32393

Detalles Bibliográficos
Autores: Izquierdo, Conchita, Salleras i Sanmartí, Lluís, Domínguez García, Àngela
Tipo de recurso: capítulo de libro
Estado:Versión publicada
Fecha de publicación:2012
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/32192
Acceso en línea:https://hdl.handle.net/2445/32192
Access Level:acceso abierto
Palabra clave:Farmacologia
Pneumònia adquirida a la comunitat
Vacunes
Pharmacology
Community-acquired pneumonia
Vaccines
id ES_fc2eb428c44efd3257c242f38d3e13f2
oai_identifier_str oai:diposit.ub.edu:2445/32192
network_acronym_str ES
network_name_str España
repository_id_str
spelling Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?Izquierdo, ConchitaSalleras i Sanmartí, LluísDomínguez García, ÀngelaFarmacologiaPneumònia adquirida a la comunitatVacunesPharmacologyCommunity-acquired pneumoniaVaccinesPodeu consultar el llibre complet a: http://hdl.handle.net/2445/32393Although bacteremic pneumococcal pneumonia is the most severe form of pneumonia, non-bacteremic forms are much more frequent. Laboratory methods for the diagnosis of nonbacteremic pneumococcal pneumonia have a low sensitivity and specificity, and therefore all-cause pneumonia has been proposed as a suitable outcome to evaluate vaccination effectiveness. This work reviews the epidemiology of community-acquired pneumonia (CAP) and evaluates the effectiveness of the 3-valent pneumococcal polysaccharide vaccine (PPV-23) in preventing CAP requiring hospitalization in people aged ≥65 years. We performed a case-control study in patients aged ≥65 years admitted through the emergency department who presented with clinical signs and symptoms compatible with pneumonia. We included 489 cases and 1,467 controls and it was obtained a vaccine efectiveness of 23.6 (0.9-41.0). Our results suggest that PPV-23 vaccination is effective and reduces hospital admissions due to pneumonia in the elderly, strengthening the rationale for vaccination programmes in this age group.Transworld Research Network2012info:eu-repo/semantics/bookPartinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2445/32192Llibres / Capítols de llibre (Medicina)reponame:Dipòsit Digital de la UBinstname:Universidad de BarcelonaInglésReproducció del capítol 5 del llibre publicat a: http://www.trnres.com/ebookcontents.php?id=131Recent Advances in Pharmaceutical Sciences II, 2012, Editor: Diego Muñoz-Torrero, Diego Haro and Joan Vallès, Chapter 5, p. 69-87.(c) Transworld Research Network , 2012info:eu-repo/semantics/openAccessoai:diposit.ub.edu:2445/321922026-05-27T06:46:51Z
dc.title.none.fl_str_mv Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?
title Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?
spellingShingle Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?
Izquierdo, Conchita
Farmacologia
Pneumònia adquirida a la comunitat
Vacunes
Pharmacology
Community-acquired pneumonia
Vaccines
title_short Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?
title_full Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?
title_fullStr Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?
title_full_unstemmed Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?
title_sort Is the 23-valent pneumococcal polysaccharide vaccine useful in preventing community-acquired pneumonia?
dc.creator.none.fl_str_mv Izquierdo, Conchita
Salleras i Sanmartí, Lluís
Domínguez García, Àngela
author Izquierdo, Conchita
author_facet Izquierdo, Conchita
Salleras i Sanmartí, Lluís
Domínguez García, Àngela
author_role author
author2 Salleras i Sanmartí, Lluís
Domínguez García, Àngela
author2_role author
author
dc.subject.none.fl_str_mv Farmacologia
Pneumònia adquirida a la comunitat
Vacunes
Pharmacology
Community-acquired pneumonia
Vaccines
topic Farmacologia
Pneumònia adquirida a la comunitat
Vacunes
Pharmacology
Community-acquired pneumonia
Vaccines
description Podeu consultar el llibre complet a: http://hdl.handle.net/2445/32393
publishDate 2012
dc.date.none.fl_str_mv 2012
dc.type.none.fl_str_mv info:eu-repo/semantics/bookPart
info:eu-repo/semantics/publishedVersion
format bookPart
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/32192
url https://hdl.handle.net/2445/32192
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del capítol 5 del llibre publicat a: http://www.trnres.com/ebookcontents.php?id=131
Recent Advances in Pharmaceutical Sciences II, 2012, Editor: Diego Muñoz-Torrero, Diego Haro and Joan Vallès, Chapter 5, p. 69-87.
dc.rights.none.fl_str_mv (c) Transworld Research Network , 2012
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Transworld Research Network , 2012
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Transworld Research Network
publisher.none.fl_str_mv Transworld Research Network
dc.source.none.fl_str_mv Llibres / Capítols de llibre (Medicina)
reponame:Dipòsit Digital de la UB
instname:Universidad de Barcelona
instname_str Universidad de Barcelona
reponame_str Dipòsit Digital de la UB
collection Dipòsit Digital de la UB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425398462283776
score 15.301603

Similares en LA Referencia